Before joining Hexagon Bio, Dr. Arvedson held senior leadership roles at Amgen, including Executive Director of Oncology Research and Global Fastlane Network Lead, where she advanced bispecific T cell engager therapies, CAR T-cell programs, and the landmark KRAS G12C inhibitor Lumakras™, which earned the 2025 ACS Heroes of Chemistry Award.